COMPASS Pathways (CMPS) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

CMPS COMPASS Pathways

Watchlist

3.930
-0.270-6.43%

Close Dec 18 16:00 ET

268.89MMarket Cap-1.80P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Compass Pathways Common Stock To Be Added To The Nasdaq Biotechnology Index
BenzingaDec 18 06:31 ET
Earnings Week Ahead: FDX, NKE, CCL, BB, ACN, MU, and More
Seeking AlphaDec 13 15:50 ET
Compass Pathways to Participate in December Investor Conferences
BusinesswireNov 25 16:00 ET
COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co?
BenzingaNov 25 14:50 ET
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
MT NewswiresNov 21 11:20 ET
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
BenzingaNov 15 10:12 ET

Comments

Stock_Drift

21 hours ago

$COMPASS Pathways (CMPS.US)$

IDKWTFIMDOING

Jul 22 04:21

$COMPASS Pathways (CMPS.US)$
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs

Jaguar8

May 8 05:31

$COMPASS Pathways (CMPS.US)$
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Jaguar8

May 2 06:00

$COMPASS Pathways (CMPS.US)$
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Moomoo AI

Jan 3 10:34

Cody Shandraw of Ambria Capital suggests FDA approval for MDMA legalization could be imminent, asserting that MDMA therapy might follow a similar trajectory to JNJ's Spravato treatment for depression. He is thrilled about the potential coverage of the therapy by the U.S. Department of Veterans Affairs for military personnel.

Why One Backer of MDMA Therapy Sees 'Exponential' Growth Following FDA Approval This Year

Heat List

Overall

No Data